...+ Jordan-based and U.K.-listed generic pharmaceutical company Hikma Pharmaceuticals PLC (Hikma) is proposing to issue benchmark-size unsecured notes to refinance its Bedford acquisition bridge facility. + Hikma is a global manufacturer of branded and generic injectable drugs. + We have assessed the business risk profile as "fair" and financial risk profile as "intermediate." + We are therefore assigning our '##+' long-term corporate credit rating to Hikma. + The stable outlook reflects our view on Hikma's stable operating performance and our leverage expectation to remain in the intermediate financial risk category LONDON (Standard & Poor's) March 25, 2015--Standard & Poor's Ratings Services today assigned its '##+' corporate credit rating to Hikma Pharmaceuticals PLC (Hikma), a Jordan-based generic pharmaceutical company. The outlook is stable. At the same time, we assigned our '##+' issue rating to Hikma's proposed senior unsecured notes. The rating reflects our assessment of Hikma's...
